Beam Therapeutics develops gene editing medicines that change single DNA bases to treat serious diseases. It last closed at $20.90 on Nov 20, down 0.19% on the day. The next earnings report for BEAM is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, BEAM reported EPS of -$1.28 on revenue of $307,000, with revenue down 96.8% from a year ago. Over its last 8 reports the stock moved an average of 9.7% the session after earnings. Over the last 12 months BEAM insiders bought $0 of stock on the open market and sold $19.7M, according to SEC Form 4 filings.
AI Auto Pilots
Is BEAM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BEAM.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on BEAMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
BEAM · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 18% below its 20 day and 18% below its 50 day average. It is 33% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $20.26, and the nearest resistance the Pivot at $21.18.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.2%/day
Key levels
$38.2652 week high+83.1%
$27.72200 day average+32.6%
$26.62100 day average+27.4%
$25.29Swing high (Oct 22)+21.0%
$24.7520 day average+18.4%
$24.6350 day average+17.8%
$21.82Pivot R1+4.4%
$21.18Pivot+1.3%
$20.90Last close
$20.26Pivot S1−3.1%
$20.2352 week low−3.2%
Indicators
RSI (14)
35.86
Weak, oversold below 30
Neutral
MACD
-1.20
Below its signal line
Bearish
Stochastic
6.1
Near the bottom of its range
Oversold
ADX (14)
20.4
Weak trend
Williams %R
-93.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-114.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.9%
Change over 10 sessions
Bearish
ATR (14)
$1.72
Typical daily range, 8.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 17.7%/day
Key levels
$38.2652 week high+83.1%
$27.72200 day average+32.6%
$26.62100 day average+27.4%
$25.29Swing high (Oct 22)+21.0%
$24.7520 day average+18.4%
$24.6350 day average+17.8%
$21.82Pivot R1+4.4%
$21.18Pivot+1.3%
$20.90Last close
$20.26Pivot S1−3.1%
$20.2352 week low−3.2%
Indicators
RSI (14)
39.32
Weak, oversold below 30
Neutral
MACD
-1.32
Below its signal line
Bearish
Stochastic
16.1
Near the bottom of its range
Oversold
ADX (14)
20.9
Weak trend
Williams %R
-95.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-165.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.9%
Change over 10 sessions
Bearish
ATR (14)
$3.69
Typical daily range, 17.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BEAM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how BEAM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow BEAM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for BEAMHow many large options trades hit BEAM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in BEAM in the last 90 days.
From SEC Form 4 filings by BEAM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BEAM is in one of them and how their past BEAM trades turned out.
Beam Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that develops gene editing medicines for patients with serious diseases. Its main approach is base editing, which changes a single DNA letter without cutting both strands of the DNA. Its lead programs target sickle cell disease and certain inherited liver and metabolic disorders. The company also has its own manufacturing capabilities for these therapies.